Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 363.5 DKK -0.58% Market Closed
Market Cap: 90.3B DKK

Relative Value

The Relative Value of one GMAB stock under the Base Case scenario is 2 499.91 DKK. Compared to the current market price of 1 363.5 DKK, Genmab A/S is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GMAB Relative Value
Base Case
2 499.91 DKK
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
56
Median 3Y
10.3
Median 5Y
13.6
Industry
7.2
Forward
3.4
vs History
98
vs Industry
7
Median 3Y
32
Median 5Y
32.8
Industry
21.4
Forward
12.8
vs History
98
vs Industry
8
Median 3Y
26.8
Median 5Y
28.7
Industry
20.4
vs History
98
vs Industry
7
Median 3Y
29.2
Median 5Y
30.5
Industry
24.5
vs History
98
vs Industry
25
Median 3Y
5.9
Median 5Y
6.7
Industry
2.4
vs History
98
vs Industry
53
Median 3Y
8.8
Median 5Y
12.1
Industry
7.4
Forward
2.6
vs History
38
vs Industry
47
Median 3Y
4.2
Median 5Y
0
Industry
9.1
vs History
98
vs Industry
7
Median 3Y
22.1
Median 5Y
22.4
Industry
4.1
Forward
7.9
vs History
98
vs Industry
7
Median 3Y
22.1
Median 5Y
23
Industry
3.8
Forward
8.5
vs History
98
vs Industry
9
Median 3Y
22.4
Median 5Y
24.7
Industry
5.1
vs History
98
vs Industry
8
Median 3Y
24.1
Median 5Y
26.4
Industry
3.3
vs History
98
vs Industry
18
Median 3Y
18.8
Median 5Y
22.8
Industry
4.4

Multiples Across Competitors

GMAB Competitors Multiples
Genmab A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Genmab A/S
CSE:GMAB
86.6B DKK 4 11 8.9 9.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 666 747.8 -174 271.6 -211 621.3 -209 206.4
US
Abbvie Inc
NYSE:ABBV
370.7B USD 6.6 87.5 17.1 25.8
US
Amgen Inc
NASDAQ:AMGN
169.7B USD 5.1 41.5 16.7 29.5
US
Gilead Sciences Inc
NASDAQ:GILD
133.4B USD 4.6 278 10.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.3B USD 11.7 -241.4 26.5 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 921.3 -490.3 -533.9 -519.7
AU
CSL Ltd
ASX:CSL
123B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.2B USD 5.1 16.4 10.7 12
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.7 -61 -55.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.6B USD 16.3 -131.7 -290.8 -197.7
P/S Multiple
Revenue Growth P/S to Growth
DK
Genmab A/S
CSE:GMAB
Average P/S: 3 333 522.4
4
14%
0.3
FR
Pharnext SCA
OTC:PNEXF
36 666 747.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 921.3
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
28%
0.6
P/E Multiple
Earnings Growth PEG
DK
Genmab A/S
CSE:GMAB
Average P/E: 77.1
11
12%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 271.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.5
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
278
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -131.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBITDA: 15.4
8.9
21%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 621.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.7
14%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -290.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBIT: 20
9.4
19%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 206.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.5
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -197.7 N/A N/A